Vertex slides as Q1 revenue miss and reiterated 2026 outlook temper enthusiasm
VRTX•Vertex Pharmaceuticals shares are sliding after first-quarter 2026 results released after the May 4 close, as the market focuses on a revenue miss versus expectations despite a profit beat. The company reiterated full-year 2026 revenue guidance of $12.95 billion to $13.10 billion, limiting upside catalysts for the stock today.
1. What’s moving the stock
Vertex Pharmaceuticals (VRTX) is trading lower today as investors digest the company’s first-quarter 2026 earnings released after the market close on May 4, 2026. While profitability was strong, the stock is reacting to top-line performance that came in below some Wall Street expectations and to an outlook that was reiterated rather than raised, reducing the scope for near-term estimate upgrades. (stockstory.org)
